Neuropharmacology, Addiction and Behaviour

In general, the research projects are devoted to studies on basic neurobiology, experimental behavioural neuroscience, physiological and pathophysiological mechanisms in the brain, and neuropharmacology of relevance for substance use disorders, especially alcohol use disorder, and neurodegenerative diseases. Of special interest in the research group is to combine neurobiological and behavioural evaluation to investigate how the association between neurobiology, behavioural characteristics, such as risk taking behaviour, and drug consumption patterns can determine individual high or low risk to develop addiction.

The experimental behavioural neuroscience is led by Dr Erika Roman. A number of behavioural models within the field of neuroscience and neuropharmacology are employed including tests for assessment of neonatal development, exploratory behaviour, locomotor activity, risk taking behaviour, self-administration, learning and memory and a multivariate test arena (the multivariate concentric square field™, MCSF) in combination with multivariate data analysis approaches. See also Uppsala University Behavioral Facility  (UUBF).

The neurobiology and neuropharmacology projects are led by Dr Ingrid Nylander and Dr Anne-Lie Svensson, respectively. Neurobiological assessment includes methods to analyse effects on receptors, transmitters and mRNA in tissue samples and brain slices but also analysis of transmitter release and re-uptake patterns using in vivo chronoamperometric analysis using Fast Analytical Sensing Technology (FAST). In vitro work includes cell models to examine detailed cellular mechanisms.

Principal investigators: Ingrid Nylander, Erika Roman, Anne-Lie Svensson